Harbin Honor Pharmaceutical Co., Ltd. Stock Code: 002437 Stock Abbreviation: Honor Pharmaceutical Announcement No.: 2026-019
Harbin Honor Pharmaceutical Co., Ltd. 2025 Board of Directors Work Report
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
In 2025, the Board of Directors of Harbin Honor Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") strictly followed the provisions of the "Company Law," "Securities Law," "Stock Listing Rules of the Shenzhen Stock Exchange," "Shenzhen Stock Exchange Main Board Listed Company Self-Regulatory Guidelines No. 1 - Standardized Operation of Main Board Listed Companies," "Articles of Association," and "Board of Directors Meeting Rules" and other relevant laws, regulations, and company systems. The Board diligently performed its duties entrusted by the shareholders' (general) meeting, conscientiously carried out various tasks, actively promoted the implementation of various resolutions of the Board, continuously standardized corporate governance, and protected the legitimate rights and interests of the Company and all shareholders. The work of the Board of Directors in 2025 is hereby reported as follows:
I. Board of Directors' Daily Work
(I) Board Meetings Held
In 2025, the Board of Directors held 8 meetings, reviewing a total of 43 proposals. All meetings were held in accordance with procedures and regulations, and all resolutions were legal and valid. The specific details of the Board meetings are as follows: